Lazard Capital Raises Abiomed to Buy (ABMD)

By admin | 6 years ago

Abiomed (NASDAQ: ABMD) was upgraded by Lazard Capital from a “neutral” rating to a “buy” rating in a research note issued on Monday.

Other equities research analysts have also recently issued reports about the stock. Analysts at Zacks reiterated an “outperform” rating on shares of Abiomed in a research note to investors on Monday, May 28th. They now have a $25.00 price target on the stock. Separately, analysts at MKM Partners raised their price target on shares of Abiomed from $27.00 to $29.00 in a research note to investors on Thursday, May 17th. They now have a “buy” rating on the stock. Finally, analysts at Wunderlich raised their price target on shares of Abiomed from $27.00 to $29.00 in a research note to investors on Thursday, May 17th. They now have a “buy” rating on the stock.

Abiomed traded up 3.09% on Monday, hitting $20.38. Abiomed has a 1-year low of $9.98 and a 1-year high of $26.17. The company has a market cap of $791.6 million and a price-to-earnings ratio of 494.25.

Abiomed last released its earnings data on Wednesday, May 16th. The company reported $0.07 EPS for the quarter, meeting the Thomson Reuters consensus estimate of $0.07. The company’s quarterly revenue was up 30.9% on a year-over-year basis. Analysts expect that Abiomed will post $0.04 EPS next quarter.

Abiomed, Inc. is a provider of medical devices in circulatory support and offers a continuum of care in heart recovery to acute heart failure patients.

About the author